TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01479452

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bariatric surgery
Description: Gastric banding, vertical banded gastroplasty, gastric bypass

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Non-surgical obesity treatment
Study: NCT01927757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered by subcutaneous injection
Study: NCT02497287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine (Intranasal Spray)
Description: Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 \>= 65 years old will start at a dose of 28 mg in Week 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine (Oral Antidepressant)
Description: Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram (Oral Antidepressant)
Description: Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants \>= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline (Oral Antidepressant)
Description: Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Description: Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants \< 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants \>= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
Study: NCT01927757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Background methotrexate at least 15 mg weekly
Study: NCT02110771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GAÏA - facial affect recognition targeted
Description: 2 sessions of one hour per week with therapist. Intervention proposes 3 stages : 1)discovering and learning facial affects recognition and discrimination criterions for joy, sadness and anger (photos exercises); 2) facial affect recognition training (computer based and role game exercises); 3) generalization to other emotions (photos, role games and computer based exercises).~The therapist chooses the change of stages; 5 sessions or more are proposed for the generalization stage.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RECOS - attentional process targeted
Description: 2 sessions of one hour per week with therapist the first of those two session is allocated to paper and pen exercises (search and validation of strategies to resolve cognitive training exercises or functional problems). the second session is allocated to computer based exercises.
Study: NCT01455558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pletaal
Description: Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state~Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state~Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart
Study: NCT04291079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SRK-181
Description: anti-latent TGFβ1 monoclonal antibody
Study: NCT02221401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin FDC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT01946022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: randomization between the two GnRH analogues (agonist and antagonist)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: randomization between the two GnRH analogues (agonist and antagonist)
Study: NCT03657498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined orthodontic-orthognathic treatment
Description: combined treatment including orthodontics and orthognathic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard orthodontic treatment
Description: treatment with standard orthodontic procedures
Study: NCT02357030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl-P plus GWI Nutrient Formula
Description: Week 1:~* One tablet of Methyl-P (5mg) twice daily~* Four tablets of GWI Nutrient Formula twice daily~Week 2 to Week 12 :~* Two tablets of Methyl-P (10mg) twice daily~* Four tablets of GWI Nutrient Formula twice daily
Study: NCT04291079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SRK-181
Description: anti-latent TGFβ1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SRK-181
Description: anti-latent TGFβ1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-PD-(L)1 antibody therapy
Description: approved anti-PD-(L)1 antibody therapy for each tumor type

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-PD-(L)1 antibody therapy
Description: approved anti-PD-(L)1 antibody therapy for each tumor type

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-PD-(L)1 antibody therapy
Description: approved anti-PD-(L)1 antibody therapy for each tumor type
Study: NCT01519609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bowel prep before endoscopy
Description: bowel prep before colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bowel prep before endoscopy
Description: bowel prep before colonoscopy
Study: NCT01830114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web app
Description: The Checkup and Choices web application
Study: NCT03595826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurostimulant pharmaceutical drugs
Description: The Pi will only administer the exercise intervention. This will consist of minimum of 8 sessions of group exercises, working on improving muscle tone, core stability, balance, fine and gross motor skills and visual motor integration. The pharmacological therapy will be administered and monitored by medical practitioners, as is the norm with most children diagnosed and treated for ADHD/ADD. Parents of participants will remain responsible entirely for the monitoring of the pharmacological therapy of their children.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurostimulant pharmaceutical drugs
Description: The Pi will only administer the exercise intervention. This will consist of minimum of 8 sessions of group exercises, working on improving muscle tone, core stability, balance, fine and gross motor skills and visual motor integration. The pharmacological therapy will be administered and monitored by medical practitioners, as is the norm with most children diagnosed and treated for ADHD/ADD. Parents of participants will remain responsible entirely for the monitoring of the pharmacological therapy of their children.
Study: NCT01005836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for youth anxiety

Intervention type: OTHER
Group type: OTHER
Intervention: Usual clinic care

Intervention type: OTHER
Group type: OTHER
Intervention: Usual clinic care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for youth depression
Study: NCT03943251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC113995PA•H2O tablet
Description: 2.5-、5-、10-、20-、40-、60-、80mg HEC113995PA•H2O tablet in day1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 2.5-、5-、10-、20-、40-、60-、80mg Placebo tablet in day1.
Study: NCT02887209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Cognitive behavioural therapy for insomnia (CBT-I; Edinger \& Carney, 2008) is a standard 4-session cognitive behavioural therapy for insomnia administered biweekly in individual format. The first session involves presenting treatment rationale and introducing a behavioural treatment regimen consisting of a series of sleep habit parameters to follow, and determining a personalized time in bed prescription. The second session involves reviewing past-week sleep diary, discussing the role of cognitions in insomnia, and discussing constructive worrying techniques and the use of thought records. The third and fourth sessions are used to assist in adjusting time in bed prescriptions, to positively reinforce efforts, and to help problem-solve any problems they might have encountered.
Study: NCT03019510

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: No exercise will be done on the day of the study night to be tested

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No exercise
Description: No exercise will be done on the day of the study night to be tested

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No exercise
Description: No exercise will be done on the day of the study night to be tested

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Morning exercise
Description: Early morning exercise will be done on the day of the study night to be tested

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Morning exercise
Description: Early morning exercise will be done on the day of the study night to be tested

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Morning exercise
Description: Early morning exercise will be done on the day of the study night to be tested

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evening exercise
Description: Evening exercise will be done on the day of the study night to be tested
Study: NCT02437214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of music for anxiety in children
Description: The Baby Go to Sleep CD played a combination of the sound of an actual human heartbeat and children's songs. The concept behind the Baby Go to Sleep CD is to blend heart beat sounds, which are known to be calming to infants and children, with children's music. The basic principles of relaxation were incorporated in the arrangements of heartbeat and children's songs, ie: simplicity, repetition, predictability, and simple symmetry (short repeated patterns). The adult human heart in the Baby Go to Sleep CD was recorded from the chest and set in consistent tempos for each song ranging from 62 to 78 beats per minute(BPM). The sound of the heartbeat continued between and during songs. Tempo changes occurred between each song.
Study: NCT03019510

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evening exercise
Description: Evening exercise will be done on the day of the study night to be tested

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Evening exercise
Description: Evening exercise will be done on the day of the study night to be tested
Study: NCT02330432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterium w
Description: Single daily dose of 0.3 mL of Mw (heat-inactivated Mw \[0.5 × 10\^9\]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best standard care
Description: Antibiotics as early as possible; Norepinephrine \> vasopressin \> epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best standard care
Description: Antibiotics as early as possible; Norepinephrine \> vasopressin \> epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles
Study: NCT03166943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systolic function by echocardiography
Description: Echocardiography for evaluation of systolic function:~* by biplane Simpson's method.~* by speckle tracking:

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diastolic function by echocardiography
Description: Echocardiography for evaluation of diastolic function:~* Left atrial Volume~* Mitral Inflow Patterns~  * Pulsed wave Doppler~ * Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns.~* Tissue Doppler Annular Early and Late Diastolic Velocities~  * Pulsed wave tissue doppler imaging~ * Primary measurements include the systolic , early diastolic, and late diastolic velocities.
Study: NCT02690025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP1848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP1848
Study: NCT04246216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrical Nerve Stimulation
Description: Experimental: Percutaneous Electrical Nerve Stimulation The experimental group will receive 3 sessions (once per week) of ultrasound-guided Percutaneous Electrical Nerve Stimulation targeted the median nerve. Once the median nerve is ultrasound identified, the needles will be left in situ at the identified points connected to an electrostimulator (ES-160 ITO co.) applying a biphasic continuous waveform, at low frequency (2 Hz)19 and with 250 microseconds pulse duration for 30mins.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic surgery of the carpal tunnel
Description: The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
Study: NCT00568061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric oxide for inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nitrogen gas (placebo) for inhalation
Study: NCT02154503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: topical 5% Minoxidil (Microneedling)
Study: NCT02973724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
Study: NCT02243280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: Tablet
Study: NCT04149925

Intervention type: DEVICE
Intervention: AEON Endostapler
Description: Surgery with AEON Endostapler

Intervention type: DEVICE
Intervention: Echelon Flex Powered Stapler
Description: Surgery with Echelon Flex Powered Stapler
Study: NCT03834233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
Study: NCT01003457

Intervention type: OTHER
Intervention: ultrasonography
Description: transvaginal ultrasonography of bladder wall thickness
Study: NCT01590290

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: financial compensation
Description: financial monetary reimbursement
Study: NCT04332523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive a single oral dose of JNJ-53718678 suspension on Day 1.
Study: NCT02690025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP1848
Study: NCT02973724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Description: Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.
Study: NCT05140746

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT
Description: Baseline 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans before NAC followed by abdomen 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans after one cycle of NAC treatment or before surgery.
Study: NCT02662725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPILIMUMAB

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Study: NCT00800969

Intervention type: PROCEDURE
Group type: OTHER
Intervention: FDG-PET-CT
Description: Radiologic standard procedure
Study: NCT00317135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Meningitec conjugate vaccine
Description: The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Meningitec conjugate vaccine
Description: The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Meningitec conjugate vaccine
Description: The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix/Hiberix vaccine
Description: The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
Study: NCT00828542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etonogestrel implant
Description: Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: depot medroxyprogesterone acetate
Description: 150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery
Study: NCT03627130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate
Description: Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Chloride
Description: Potassium Chloride capsules for 5 days